C4 Therapeutics stockholders elect directors, approve equity plan amendment including pre-funded warrants

C4 Therapeutics, Inc.

Three Class III directors (Hirsch, Fawell, Koppikar) re-elected with 47.8M–46.5M votes for each.
Non-binding advisory vote on executive compensation approved: 54.9M for, 1.07M against.
Stockholders ratified KPMG as independent auditor for fiscal 2026 with 76.9M votes in favor.
Amendment to 2020 Stock Plan approved: includes pre-funded warrants in Outstanding Shares definition for evergreen increase calculation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.